ReviewJournal of cellular and molecular medicine2023

Pre-clinical evidence of a dual NADPH oxidase 1/4 inhibitor (setanaxib) in liver, kidney and lung fibrosis.

Victor J Thannickal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.